The dada-meets-Renaissance aesthetic of the curator’s palazzo on Venice’s Grand Canal is a monument to his late father — and ...

U.S. stock indexes are edging back from their record levels on Tuesday as an incredibly busy week for Wall Street picks up momentum.

Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $71.01, denoting a +1.89% move from the preceding trading day.

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still likely to ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance ...

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building a stake in the Ozempic maker.

Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks. See why NVO stock is a Strong Buy.

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 2024.

Novo Nordisk (NYSE: NVO) stock tumbled 3.9% through 10:45 a.m. ET this morning after the manufacturer of GLP-1 weight loss drugs announced its CEO, Lars Fruergaard Jørgensen, will step down from ...